La Frazia S, Pauciullo S, Zulian V, Garbuglia A
Viruses. 2025; 16(12.
PMID: 39772271
PMC: 11728759.
DOI: 10.3390/v16121965.
Gawi Ermi A, Sarkar D
Cancers (Basel). 2024; 16(23).
PMID: 39682130
PMC: 11640171.
DOI: 10.3390/cancers16233944.
Cigliano A, Liao W, Deiana G, Rizzo D, Chen X, Calvisi D
Biomedicines. 2024; 12(7).
PMID: 39062197
PMC: 11274649.
DOI: 10.3390/biomedicines12071624.
Chu P, Hsu C, Lin Y, Pan Y, Dai Y, Yu Y
Heliyon. 2024; 10(2):e24438.
PMID: 38312542
PMC: 10835261.
DOI: 10.1016/j.heliyon.2024.e24438.
Wang K, Liao P, Chang W, Yang C, Su Y, Wu P
Front Pharmacol. 2024; 14:1281067.
PMID: 38293667
PMC: 10824963.
DOI: 10.3389/fphar.2023.1281067.
The Significance of N6-Methyladenosine RNA Methylation in Regulating the Hepatitis B Virus Life Cycle.
Moon J, Lee W, Cho Y, Kim Y, Kim G
J Microbiol Biotechnol. 2023; 34(2):233-239.
PMID: 37942519
PMC: 10940779.
DOI: 10.4014/jmb.2309.09013.
Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?.
Russo F, Zanetto A, Pinto E, Battistella S, Penzo B, Burra P
Int J Mol Sci. 2022; 23(1).
PMID: 35008926
PMC: 8745141.
DOI: 10.3390/ijms23010500.
A Pleiotropic Role of the Hepatitis B Virus Core Protein in Hepatocarcinogenesis.
Lefeuvre C, Le Guillou-Guillemette H, Ducancelle A
Int J Mol Sci. 2021; 22(24).
PMID: 34948447
PMC: 8707456.
DOI: 10.3390/ijms222413651.
Hepatitis B Virus X Protein Expression Is Tightly Regulated by N6-Methyladenosine Modification of Its mRNA.
Kim G, Siddiqui A
J Virol. 2021; 96(4):e0165521.
PMID: 34851655
PMC: 8865537.
DOI: 10.1128/JVI.01655-21.
Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma.
Borgia M, Dal Bo M, Toffoli G
Cancers (Basel). 2021; 13(17).
PMID: 34503196
PMC: 8431318.
DOI: 10.3390/cancers13174387.
Hepatitis B Virus DNA Integration: In Vitro Models for Investigating Viral Pathogenesis and Persistence.
Tu T, Zhang H, Urban S
Viruses. 2021; 13(2).
PMID: 33530322
PMC: 7911709.
DOI: 10.3390/v13020180.
Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models.
Yeh C, Liao P, Pandey S, Yung S, Lai H, Jeng L
Front Oncol. 2020; 10:572861.
PMID: 33194674
PMC: 7609882.
DOI: 10.3389/fonc.2020.572861.
Pathological changes of liver one year later in CHB patients with negative HBV DNA.
Shanshan W, Xinfang D, Shuihong Y, Kecong L, Jinjin Q, Zhi C
Infect Agent Cancer. 2019; 14:48.
PMID: 31827599
PMC: 6902453.
DOI: 10.1186/s13027-019-0265-2.
HBV-related hepatocarcinogenesis: the role of signalling pathways and innovative ex vivo research models.
Torresi J, Tran B, Christiansen D, Earnest-Silveira L, Schwab R, Vincan E
BMC Cancer. 2019; 19(1):707.
PMID: 31319796
PMC: 6637598.
DOI: 10.1186/s12885-019-5916-6.
The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.
Gallay P, Ure D, Bobardt M, Chatterji U, Ou J, Trepanier D
PLoS One. 2019; 14(6):e0217433.
PMID: 31181107
PMC: 6557616.
DOI: 10.1371/journal.pone.0217433.
Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models.
Wang Q, Zhang P, Li Z, Feng X, Lv C, Zhang H
Theranostics. 2019; 9(5):1426-1452.
PMID: 30867842
PMC: 6401493.
DOI: 10.7150/thno.31683.
Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model.
Hu D, Wang H, Wang H, Wang Y, Wan X, Yan W
Hepatol Int. 2018; 12(5):438-446.
PMID: 29974410
DOI: 10.1007/s12072-018-9877-7.
Hepatitis B Virus Infection Dampens CtIP Expression in Hepatoma Cell.
Zhang D, Liu H, Lin J, Ye D
J Cancer. 2018; 9(7):1182-1187.
PMID: 29675099
PMC: 5907666.
DOI: 10.7150/jca.23649.
The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice.
Kang X, Guo X, Chen B, Zhang T, Yuan Q, Chen P
Hum Vaccin Immunother. 2018; 14(7):1779-1781.
PMID: 29533134
PMC: 6067855.
DOI: 10.1080/21645515.2018.1449553.
SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.
Kang H, Chung D, Sung C, Yoo S, Yu E, Kim N
Oncotarget. 2017; 8(16):27263-27276.
PMID: 28460481
PMC: 5432333.
DOI: 10.18632/oncotarget.15930.